Business Daily Media

Men's Weekly

.

China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics

  • Written by ACN Newswire - Press Releases
HONG KONG, Jun 28, 2021 - (ACN Newswire) - 2021-6-23 / Gelonghui - China Biotech's cell therapy was approved by the NMPA to enter Phase I clinical trials as a Class I new drug, while the recent CAR-T cell therapy approval for product marketing in China means a new era of immune cell therapy has begun.
Source: official website of NMPA
image
China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics
China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics
According to

Read more //?#

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

The Next Generation of Maritime Sustainable Solutions

As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

Sell by LayBy